Insider Selling: CytomX Therapeutics, Inc. (CTMX) CFO Sells 2,500 Shares of Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $18.10, for a total transaction of $45,250.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Debanjan Ray also recently made the following trade(s):
- On Friday, September 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $17.17, for a total transaction of $42,925.00.
- On Wednesday, August 9th, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $37,500.00.
CytomX Therapeutics, Inc. (CTMX) traded up 20.63% on Wednesday, reaching $22.92. 2,456,510 shares of the company were exchanged. The firm’s market capitalization is $844.99 million. CytomX Therapeutics, Inc. has a 12-month low of $9.85 and a 12-month high of $24.67. The stock has a 50 day moving average of $16.66 and a 200 day moving average of $15.57.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). The company had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. Equities analysts anticipate that CytomX Therapeutics, Inc. will post ($1.49) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/04/insider-selling-cytomx-therapeutics-inc-ctmx-cfo-sells-2500-shares-of-stock.html.
Several equities analysts have commented on the stock. Jefferies Group LLC reissued a “buy” rating and set a $25.00 target price on shares of CytomX Therapeutics in a research report on Tuesday, June 6th. Cowen and Company restated a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, June 28th. BidaskClub raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Finally, Bank of America Corporation reiterated a “buy” rating and set a $30.00 price target (up previously from $28.00) on shares of CytomX Therapeutics in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $29.86.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of CytomX Therapeutics by 0.6% in the 2nd quarter. FMR LLC now owns 5,512,459 shares of the biotechnology company’s stock valued at $85,444,000 after buying an additional 34,732 shares during the last quarter. Perceptive Advisors LLC grew its stake in shares of CytomX Therapeutics by 65.7% in the first quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock valued at $26,434,000 after buying an additional 606,896 shares in the last quarter. Vanguard Group Inc. increased its holdings in CytomX Therapeutics by 12.2% during the second quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock worth $14,323,000 after buying an additional 100,607 shares during the last quarter. EcoR1 Capital LLC acquired a new position in CytomX Therapeutics during the first quarter worth $13,729,000. Finally, Redmile Group LLC increased its holdings in CytomX Therapeutics by 2.4% during the second quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock worth $10,825,000 after buying an additional 16,500 shares during the last quarter. 59.97% of the stock is owned by institutional investors.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.